American Association for Cancer Research
Browse
10780432ccr180773-sup-198270_3_supp_5146437_phrlxf.pdf (31.96 kB)

Supplementary Data from Cancer-associated Fibroblast–promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma

Download (31.96 kB)
journal contribution
posted on 2023-03-31, 21:22 authored by Hongfang Zhang, Yuhui Hua, Zhenzhen Jiang, Jing Yue, Ming Shi, Xiaoli Zhen, Xiaoyan Zhang, Ling Yang, Rongjing Zhou, Shixiu Wu

Supplementary Figure. S3. Inhibition of DNM3OS expression improved the radiosensitivity of KYSE-150R xenograft tumors.

Funding

National Natural Science Foundation of China

Zhejiang Provincial

Zhejiang Provincial Natural Science Foundation

Zhejiang Provincial Medical Scientific Research Foundation of China

Hangzhou City Medical Scientific Research Foundation of Zhejiang Province, China

Hangzhou City Scientific Technology Research Foundation of Zhejiang Province

History

ARTICLE ABSTRACT

Our study aimed to investigate whether CAF (cancer-associated fibroblasts) were involved in long noncoding RNAs (lncRNA)-regulated radioresponse in esophageal squamous cell carcinoma (ESCC).Experimental Design: By use of lncRNAs PCR array, 38 lncRNAs were screened in esophageal cancer cells and in normal esophageal epithelial cells Het-1A. LncRNA DNM3OS was detected in tumor tissues of patients with ESCC and in matched normal esophageal epithelial tissues by qRT-PCR analysis and in situ hybridization assay. The association of DNM3OS and tumor radioresistance was investigated in vitro and in vivo. The influences of DNM3OS on DNA damage response (DDR) was investigated by Western blotting, immunofluorescence imaging, and comet assay. The mechanisms by which CAFs promoted DNM3OS expression was investigated by kinase inhibitors' screening, luciferase assay, and chromatin immunoprecipitation. Among the 38 lncRNAs tested, DNM3OS was found to have a much higher expression level in esophageal cancer cells than in Het-1A. In tumor tissues of 16 patients with ESCC, the expression level of DNM3OS showed an average increase of 6.3429-fold compared with that in matched normal tissues. DNM3OS conferred significant radioresistance in vitro and in vivo by regulating DDR. CAFs promoted the expression of DNM3OS with a 39.2554-fold and 38.3163-fold increase in KYSE-30 and KYSE-140, respectively. CAFs promoted the expression of DNM3OS in a PDGFβ/PDGFRβ/FOXO1 signaling pathway–dependent manner. FOXO1, a transcription factor downstream of PDGFβ/PDGFRβ signaling pathway, initiated the transcription of DNM3OS by binding to DNM3OS promoter. Our study highlighted CAF-promoted DNM3OS as an attractive target to reverse tumor radioresistance in ESCC.